Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00057395
Status:
UNKNOWN
Last Update Posted:
2005-06-24
First Post:
2003-04-01
Brief Title:
A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies
Sponsor:
Aronex Pharmaceuticals
Organization:
Aronex Pharmaceuticals
Study Overview
Official Title:
A Phase III Study of Aroplatin in Patients With Advanced Solid Malignancies
Status:
UNKNOWN
Status Verified Date:
2004-04
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the rate of response and the duration of the response following therapy with Aroplatinin patients with advanced solid malignancies
Detailed Description:
Primary Objective
Determine response rate RR complete and partial response CR PR and duration after therapy with Aroplatin in patients with advanced solid malignancies
Secondary Objective
Determine the safety and tolerability of Aroplatin
Determine response rate RR complete and partial response CR PR and duration after therapy with Aroplatin in patients with advanced solid malignancies
Secondary Objective
Determine the safety and tolerability of Aroplatin
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None